Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Memphasys Ltd ( (AU:MEM) ) has provided an update.
Memphasys has secured CE Mark approval under the European Union Medical Device Regulation for its Felix™ automated sperm selection system, allowing commercial sale and clinical use across the European Economic Area and other CE-recognising jurisdictions, and positioning the product as a globally deployable commercial platform. The certification immediately unlocks an estimated annual addressable market of more than €29 million in Europe alone, activates multi-year distribution and supply agreements in Europe and the MENA region worth over A$1.3 million in minimum contracted purchases, and supports the company’s transition into a revenue-scaling phase, with early cartridge orders, clinics prepared for immediate adoption, and additional regulatory clearances in India and Australia expected to follow under mutual recognition pathways.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
More about Memphasys Ltd
Memphasys Limited is an Australian-based medical technology company focused on reproductive health, developing and commercialising its Felix™ automated sperm selection system for use in assisted reproductive technology (ART) and IVF clinics, particularly targeting intracytoplasmic sperm injection (ICSI) procedures in major global fertility markets.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$13.07M
See more data about MEM stock on TipRanks’ Stock Analysis page.